2. Investors

INVESTOR RELATIONS

For 25 years, RaySearch Laboratories has been creating value by advancing cancer treatment through software innovation. We have the ambition to keep you updated about our performance and other factors contributing to your assessment of RaySearch as an investment. 

RAYSEARCH'S Q3 INTERIM REPORT

RaySearch will publish its interim report for the third quarter of 2025 on Friday November 7 at 7.45 CET. A webcast presentation will be held at 10:00 the same day.

Webcast presentation

Latest press releases

RaySearch receives additional RayStation order for advanced proton therapy at Stanford Health Care

Invitation to presentation of RaySearch’s interim report for the third quarter of 2025

RaySearch Brings Next-Level Innovation to ASTRO 2025

All press releases

Latest reports

Interim report April - June 2025

Interim report January 1 – March 31, 2025

Clarification and supplementation of previous press release on publication of RaySearch Annual Report for 2024

All financial reports

Financial calendar

Interim report third quarter, 2025

Year-end report 2025

More upcoming events

Share data

Latest update

The RaySearch B share is listed in the Mid Cap segment on the NASDAQ OMX Nordic Exchange.

Net sales & Operating profit

Annual Report 2024

Annual Report 2024
RaySearch Annual Report 2024, ESEF
Previous Annual Reports

Corporate Governance

Corporate governance is about structure and accountability. Read more about how we govern RaySearch for sustainable value creation.

Our Organization

Meet our senior management team and board of directors

IR contact